Faculty Opinions recommendation of Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure.
This trial assessed the risk of clinical progression in surviving patients with heart failure when treated with an inhibitor of angiotensin neprilysin compared with the angiotensin-converting enzyme (ACE) inhibitor enalapril. The investigators found that the clinical progression of surviving patients with heart failure was prevented more effectively by angiotensin-neprilysin inhibition than by ACE inhibition. This Recommendation is of an article referenced in an F1000 Faculty Review also written by WH Wilson Tang and Takeshi Kitai.